Should we use the growth modulation index (GMI) in response assessment in G2 neuroendocrine tumours (NETs)?

#4657

Introduction: Grade 2 (G2) neuroendocrine tumours (NETs) exhibit diverse behaviours ranging from indolent to aggressive malignancies. Growth Modulation Index (GMI) is the ratio between time to progression (TTP) with a line of therapy (TTPn) and that of the previous line of therapy (TTPn-1). A GMI value equal to or greater than 1,33 has been suggested as an indicator of clinical effectiveness beyond traditional metrics.

Aim(s): To explore the possible role of GMI in the assessment of response to treatments in G2 NETs.

Materials and methods: We retrospectively selected patients (pts) with a centrally analysed histological diagnosis of G2 gastroenteropancreatic NET treated between 2011 and 2022 in our institute who received at least two lines of systemic treatments. Radiological disease progression to both lines was required in order to calculate GMI.

Conference:

Presenting Author: Bertuzzi A

Authors: Bertuzzi A, Ferrillo G, Laffi A, Evangelista L, Jandric J,

Keywords: growth modulation index (GMI), G2 gastroenteropancreatic neuroendocrine tumour (GEP-NET), tumour response assessment,